オーラルセッション
- 第4日 5月18日（金） 09:40～10:00 A会場（オービットホール）
-
4A-O1-P-0940 PDF
リン酸化プロテオーム解析を用いた非小細胞肺がん細胞株のエルロチニブ耐性機構解析と耐性克服薬の探索
Throughput and depth of mass spectrometry-based proteomics have been improved. We have developed a key technology on peptide separation for rapid and sensitive phosphoproteome analysis. Using these technologies, we compared temporal phosphoproteome and phosphotyrosine-proteome profiles of erlotinib-sensitive and resistant NSCLC cells treated by erlotinib for 0 h, 6 h and 24 h. We extracted active kinase and signaling candidates in resistant cells from phosphoproteome data and selected 46 inhibitors for drug screening. 24 of 46 inhibitors inhibited cell growth of at least one resistant cell line. Phosphoproteomic approach is applicable for the detection of the markers for drug-efficacy and the target candidates for overcoming drug resistance.